awmsg logo



lapatinib (Tyverb®)


Reference No. 178

Publication date:
15/08/2013


Last review date:
30/09/2016

Appraisal information

lapatinib (Tyverb®) 250 mg film-coated tablet


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 19/06/2013
AWMSG meeting date: 17/07/2013
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 1713
Ministerial ratification: 14/08/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Lapatinib (Tyverb®) is recommended as an option for restricted use within NHS Wales for the treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2), in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting. Lapatinib (Tyverb®) should be restricted within its licensed indication for the treatment of patients as an alternative to treatment with trastuzumab and capecitabine or trastuzumab and vinorelbine in patients in whom clinicians consider this clinically appropriate. Lapatinib (Tyverb®) is not recommended for use within NHS Wales outside of this subpopulation. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download